At the time of writing, Revance Therapeutics Inc [RVNC] stock is trading at $5.66, down -0.70%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RVNC shares have gain 5.40% over the last week, with a monthly amount drifted -6.29%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update. In a post published today on Yahoo Finance, – Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively.
From an analyst’s perspective:
Revance Therapeutics Inc [NASDAQ: RVNC] stock has seen the most recent analyst activity on January 29, 2024, when Mizuho downgraded its rating to a Neutral and also revised its price target to $9 from $16. Previously, Goldman downgraded its rating to Neutral on January 09, 2024, and dropped its price target to $8. On August 16, 2023, upgrade upgraded it’s rating to Neutral but maintained its price target of $20 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $27 on October 11, 2022. Goldman initiated its recommendation with a Buy and recommended $33 as its price target on September 22, 2022. Wells Fargo downgraded its rating to Equal Weight for this stock on October 25, 2021, and downed its price target to $17. In a note dated October 15, 2020, Needham reiterated an Buy rating on this stock and boosted its target price from $36 to $42.
For the past year, the stock price of Revance Therapeutics Inc fluctuated between $5.00 and $37.98. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Revance Therapeutics Inc [NASDAQ: RVNC] shares were valued at $5.66 at the most recent close of the market. An investor can expect a potential return of 465.37% based on the average RVNC price forecast.
Analyzing the RVNC fundamentals
According to Revance Therapeutics Inc [NASDAQ:RVNC], the company’s sales were 214.16M for trailing twelve months, which represents an 95.68% jump. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at -1.58%, Pretax Profit Margin comes in at -1.93%, and Net Profit Margin reading is -1.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is 17.93 and Total Capital is -0.75. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-4.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.51 points at the first support level, and at 5.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.75, and for the 2nd resistance point, it is at 5.84.
Revance Therapeutics Inc [RVNC] reported earnings per share of -$1.63 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.85/share, meaning a difference of -$0.78 and a surprise factor of -91.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.8 per share as compared to estimates of -$0.78 per share, a difference of -$0.02 representing a surprise of -2.60%.
Ratios To Look Out For
It is important to note that Revance Therapeutics Inc [NASDAQ:RVNC] has a current ratio of 4.73. In addition, the Quick Ratio stands at 4.17 and the Cash Ratio stands at 2.18. Considering the valuation of this stock, the price to sales ratio is 2.32.
Transactions by insiders
Recent insider trading involved Moxie Dwight, SVP, GC & Secretary, that happened on Sep 06 when 11000.0 shares were sold. SVP, GC & Secretary, Moxie Dwight completed a deal on Sep 05 to sell 23853.0 shares. Meanwhile, CEO Foley Mark J sold 26279.0 shares on Aug 03.
